CLOV Stock Price, Clover Health Investments, . Quote, Chart

Market Summary

USD0.90-0.03

Market Closed

-3.23%

CLOV Alerts

Big fall in Revenue (Y/Y)

Big jump in Earnings (Y/Y)
Losses in recent quarter

CLOV Stock Price

View Fullscreen

CLOV RSI Chart

CLOV Valuation

Market Cap

437.7M

Price/Earnings (Trailing)

-2.74

Price/Sales (Trailing)

0.24

Price/Free Cashflow

-2.58

CLOV Price/Sales (Trailing)

CLOV Profitability

Return on Equity

-54.68%

Return on Assets

-23.81%

Free Cashflow Yield

-38.78%

CLOV Fundamentals

CLOV Revenue

Revenue (TTM)

1.9B

Rev. Growth (Yr)

-34.27%

Rev. Growth (Qtr)

-32.01%

CLOV Earnings

Earnings (TTM)

-159.9M

Earnings Growth (Yr)

73.6%

Earnings Growth (Qtr)

72.8%

Breaking Down CLOV Revenue

Last 7 days

9.8%

Last 30 days

45.2%

Last 90 days

-9.1%

Trailing 12 Months

-15.1%

How does CLOV drawdown profile look like?

CLOV Financial Health

Current Ratio

1.55

CLOV Investor Care

Shares Dilution (1Y)

1.58%

Diluted EPS (TTM)

-0.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.9B	0	0	0
2023	3.1B	2.8B	2.4B	2.0B
2022	2.1B	2.6B	3.0B	3.5B
2021	707.7M	948.1M	1.2B	1.5B
2020	514.9M	567.6M	620.2M	672.9M
2019	0	0	0	462.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Clover Health Investments, Corp.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 08, 2024	toy andrew	sold (taxes)	-74,269	0.87	-85,367	chief executive officer
Apr 18, 2024	priest brady patrick	sold (taxes)	-20,422	0.63	-32,416	ceo of home care
Apr 03, 2024	reynoso jamie l.	sold (taxes)	-4,094	0.76	-5,387	ceo, medicare advantage
Apr 01, 2024	toy andrew	sold (taxes)	-237,423	0.77	-308,341	chief executive officer
Mar 15, 2024	soares karen	sold (taxes)	-4,134	0.8	-5,168	general counsel & secretary
Mar 15, 2024	reynoso jamie l.	sold (taxes)	-4,302	0.8	-5,378	ceo, medicare advantage
Mar 14, 2024	reynoso jamie l.	sold (taxes)	-5,677	0.73	-7,777	ceo, medicare advantage
Mar 14, 2024	wai conrad	sold (taxes)	-54,309	0.73	-74,396	chief technology officer
Mar 14, 2024	loengard anna u	bought	100,010	0.73	137,000	-
Mar 14, 2024	loengard anna u	bought	9,946	0.73	13,625	-

Which funds bought or sold CLOV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-50.7	-703,813	491,413	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	1.73	-48,447	271,011	-%
May 16, 2024	Jaffetilchin Investment Partners, LLC	added	30.24	3,132	39,494	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-30.43	-1,451,040	2,005,560	-%
May 15, 2024	MORGAN STANLEY	reduced	-3.7	-152,747	622,871	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	116	422,860	950,284	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-74.81	-100,718	26,791	-%
May 15, 2024	PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	new	-	3,629	3,629	-%
May 15, 2024	WEDBUSH SECURITIES INC	sold off	-100	-10,000	-	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	added	187	132	227	-%

Are Funds Buying or Selling CLOV?

Are funds buying CLOV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CLOV

No. of Funds

Unveiling Clover Health Investments, Corp.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	6.09%	24,331,680	SC 13G/A
Jul 07, 2023	blackrock inc.	2.0%	7,772,104	SC 13G/A
Feb 09, 2023	vanguard group inc	8.38%	32,158,748	SC 13G/A
Feb 03, 2023	blackrock inc.	7.1%	27,124,981	SC 13G
Oct 04, 2022	chachacha spac c, llc	4.99%	19,132,693	SC 13D/A
Mar 10, 2022	greenoaks capital partners llc	1.3%	5,073,790	SC 13G/A
Feb 09, 2022	vanguard group inc	7.83%	25,887,351	SC 13G/A
Feb 12, 2021	integrated core strategies (us) llc	0.0%	12,933	SC 13G/A
Feb 09, 2021	greenoaks capital partners llc	40.2%	96,331,338	SC 13G
Feb 04, 2021	linden capital l.p.	0.1%	70,365	SC 13G/A

Recent SEC filings of Clover Health Investments, Corp.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 10, 2024	3	Insider Trading
May 10, 2024	4	Insider Trading
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 22, 2024	4	Insider Trading

Peers (Alternatives to Clover Health Investments, Corp.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	482.9B	379.5B	9.53%	9.48%	31.44	1.27	12.96%	-25.81%
CI	96.2B	206.0B	-2.11%	32.08%	24.97	0.47	12.55%	-43.95%
HCA	84.6B	66.7B	3.80%	15.55%	15.46	1.27	9.59%	-4.59%
CVS	72.4B	360.9B	-15.92%	-16.78%	9.89	0.2	9.07%	78.49%
CNC	41.7B	155.5B	8.44%	18.66%	15.24	0.27	6.34%	84.42%
DVA	12.3B	12.3B	9.53%	38.52%	15.03	0.99	5.77%	58.74%
UHS	11.9B	14.7B	11.04%	30.82%	14.63	0.81	7.99%	19.23%
MID-CAP
CHE	8.5B	2.3B	-6.47%	5.37%	30.15	3.73	5.96%	18.29%
ACHC	6.2B	3.0B	-5.49%	-7.73%	-545.12	2.06	10.92%	-104.06%
AMEH	2.3B	1.5B	9.06%	20.53%	36.62	1.57	19.34%	40.15%
AMN	2.2B	3.5B	4.01%	-38.44%	15.49	0.64	-27.67%	-62.43%
SMALL-CAP
ADUS	1.8B	1.1B	14.53%	25.72%	27.59	1.67	11.45%	30.74%
BKD	1.3B	3.0B	6.97%	85.25%	-7.66	0.44	4.98%	4.88%
BEAT	54.5M	-	-4.17%	-6.33%	-3.61	-	-	-1.05%
AMS	22.0M	21.6M	16.05%	23.93%	39.79	1.02	9.04%	-50.63%

Clover Health Investments, Corp. News

Latest updates

Clover Health Investments, Corp. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	-32.0%	346,922	510,251	482,066	513,628	527,775	898,791	856,817	846,700	874,379	432,036	427,163	412,472	200,325	166,233	169,069	172,081	165,505	-
Gross Profit	31.3%	81,760	62,266	63,107	76,674	55,285	5,146	17,018	-12,086	12,657	-	-9,162	-46,031	-	-	-	-	-	-
Operating Expenses	-35.8%	369,625	575,911	523,535	542,435	600,381	1,006,134	930,913	949,427	961,860	618,825	576,416	594,334	319,413	233,862	190,687	148,911	192,135	-
S&GA Expenses	-100.0%	-	45,080	41,747	42,433	59,215	55,348	47,832	47,040	57,697	55,177	45,846	45,646	38,618	41,032	29,847	21,468	28,483	-
Interest Expenses	-	-	-	-	7.00	-	136	404	390	403	403	404	1,211	1,175	10,430	9,268	8,477	7,815	-
Net Income	72.8%	-19,170	-70,472	-41,469	-28,814	-72,606	-84,226	-75,489	-104,362	-75,490	-187,201	-34,527	-317,611	-48,417	-126,391	12,758	5,403	-28,162	-17.63
Net Income Margin	17.7%	-0.09*	-0.10*	-0.09*	-0.09*	-0.11*	-0.10*	-0.15*	-0.16*	-0.29*	-0.40*	-0.44*	-0.51*	-0.22*	-0.20*	-0.02*	-0.64*	-0.71*	-0.79*
Free Cashflow	111.1%	25,490	-229,031	-19,024	52,819	78,781	-295,667	101,396	-39,344	-57,200	-80,414	-45,321	-64,346	-92,968	-59,967	-34,817	13,011	-37,418	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Assets	17.7%	672	571	1,060	1,258	1,454	809	1,558	2,063	2,680	951	952	1,216	867	267	829	829	583	337
Current Assets	29.2%	553	428	916	1,129	1,274	625	1,460	1,861	2,491	753	559	718	809	190	1.00	1.00	-	253
Cash Equivalents	69.5%	208	123	299	310	191	104	383	324	274	300	202	486	405	92.00	90.00	107	112	68.00
Net PPE	2.5%	5.00	5.00	5.00	5.00	5.00	6.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	-	-	-	2.00
Goodwill	-	-	-	-	-	-	12.00	-	-	-	1.00	-	-	-	1.00	-	-	-	1.00
Liabilities	33.4%	379	284	738	927	1,130	452	1,166	1,636	2,190	411	540	901	278	433	31.00	29.00	-	378
Current Liabilities	36.5%	356	261	719	908	1,110	432	1,128	1,599	2,152	372	230	196	173	164	2.00	0.00	1.00	142
Long Term Debt	-	-	-	-	-	-	-	20.00	20.00	20.00	20.00	20.00	20.00	5.00	106	-	-	-	58.00
LT Debt, Non Current	-	-	-	-	-	-	-	20.00	20.00	20.00	20.00	20.00	20.00	24.00	106	-	-	-	58.00
Shareholder's Equity	2.1%	292	286	322	331	323	357	392	427	490	540	412	315	589	5.00	5.00	5.00	0.00	-
Retained Earnings	-0.9%	-2,178	-2,159	-2,089	-2,047	-2,019	-1,946	-1,871	-1,796	-1,692	1,616	-1,429	-1,395	-1,077	-1,028	-2.37	-0.07	-0.02	-891
Additional Paid-In Capital	1.2%	2,490	2,461	2,428	2,395	2,359	2,319	2,281	2,238	2,195	2,154	1,839	1,706	1,663	412	7.00	5.00	0.00	403
Shares Outstanding	0.9%	486	482	481	-	479	476	476	475	473	413	410	408	376	89.00	89.00	89.00	88.00	88.00
Minority Interest	-	-	-	-	-	-	-	-	-	-	4.00	4.00	4.00	4.00	4.00	-	-	-	-
Float	-	-	-	-	360	-	-	-	839	-	-	-	5,469	-	-	-	926	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	111.3%	25,935	-229,295	-18,781	53,173	79,032	-291,790	101,655	-39,171	-57,042	-80,176	-45,126	-64,155	-92,869	-59,904	-34,650	13,232	-37,176	-17.63
Share Based Compensation	-13.1%	28,798	33,136	33,070	36,108	38,617	39,094	42,644	41,927	40,640	31,181	46,803	43,026	42,713	2,129	1,501	1,471	1,977	-
Cashflow From Investing	-89.0%	9,185	83,662	-20,321	66,491	10,181	12,656	-43,389	89,353	36,513	-106,491	-242,345	170,865	-257,476	67,557	1,500	-14,163	82,510	-
Cashflow From Financing	88.7%	-3,359	-29,617	-1,963	-147	-2,134	82,478	132	458	-5,608	284,371	3,988	-25,470	662,504	-5,037	15,470	-4,151	-438	18.00
Buy Backs	306.2%	3,359	827	1,994	417	2,982	42.00	276	105	5,939	-	147	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CLOV Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Premiums earned, net (Net of ceded premiums of $101 and $122 for the three months ended March 31, 2024 and 2023, respectively)	$ 341,722	$ 317,086
Other income	5,200	4,906
Total revenues	346,922	321,992
Operating expenses:
Net medical claims incurred	265,162	274,789
Salaries and benefits	59,223	68,981
General and administrative expenses	44,569	57,644
Premium deficiency reserve benefit	0	(1,810)
Depreciation and amortization	318	279
Restructuring costs	353	1,807
Total operating expenses	369,625	401,690
Loss from continuing operations	(22,703)	(79,698)
Loss on investment	467	0
Net loss from continuing operations	(23,170)	(79,698)
Net income from discontinued operations (Note 17)	4,000	7,092
Net loss	$ (19,170)	$ (72,606)
Continuing Operations:
Basic weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares)	486,374,644	478,805,067
Diluted weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares)	486,374,644	478,805,067
Basic net loss per share (in dollars per share)	$ (0.05)	$ (0.17)
Diluted net loss per share (in dollars per share)	$ (0.05)	$ (0.17)
Discontinued operations:
Basic weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares)	486,374,644	478,805,067
Diluted weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares)	567,451,166	566,629,082
Basic earnings per share (in dollars per share)	$ 0.01	$ 0.01
Diluted earnings per share (in dollars per share)	$ 0.01	$ 0.01
Net unrealized (loss) gain on available-for-sale investments	$ (190)	$ 2,343
Comprehensive loss	$ (19,360)	$ (70,263)

CLOV Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 208,255	$ 116,407
Short-term investments	9,120	12,218
Investment securities, available-for-sale (Amortized cost: 2024: $119,528; 2023: $101,412)	118,056	100,702
Investment securities, held-to-maturity (Fair value: 2024: $6,853; 2023: $6,778)	6,923	6,902
Accrued retrospective premiums	70,607	22,076
Other receivables	22,533	16,666
Healthcare receivables	83,867	64,164
Surety bonds and deposits	740	542
Prepaid expenses	16,761	14,418
Other assets, current	4,949	1,404
Assets related to discontinued operations (Note 17)	10,926	72,471
Total current assets	552,737	427,970
Investment securities, available-for-sale (Amortized cost: 2024: $98,221; 2023: $121,868)	97,133	120,208
Investment securities, held-to-maturity (Fair value: 2024: $693; 2023: $692)	792	793
Property and equipment, net	5,209	5,082
Operating lease right-of-use assets	3,124	3,382
Other intangible assets	2,990	2,990
Other assets, non-current	9,785	10,246
Total assets	671,770	570,671
Current liabilities
Unpaid claims	238,602	135,737
Accounts payable and accrued expenses	35,408	37,184
Accrued salaries and benefits	28,327	20,951
Deferred revenue	0	3,099
Operating lease liabilities	1,623	1,665
Liabilities related to discontinued operations (Note 17)	50,622	60,099
Total current liabilities	356,389	261,115
Long-term operating lease liabilities	2,717	2,998
Other liabilities, non-current	20,190	20,164
Total liabilities	379,296	284,277
Commitments and Contingencies (Note 13)
Stockholders' equity
Additional paid-in capital	2,490,036	2,461,238
Accumulated other comprehensive loss	(2,560)	(2,370)
Accumulated deficit	(2,178,964)	(2,159,794)
Less: Treasury stock, at cost; 11,613,745 and 7,912,750 shares held at March 31, 2024 and December 31, 2023, respectively	(16,088)	(12,729)
Total stockholders' equity	292,474	286,394
Total liabilities and stockholders' equity	671,770	570,671
Common Class A
Stockholders' equity
Common stock, value	41	40
Common Class B
Stockholders' equity
Common stock, value	9	9
Related party
Current liabilities
Due to related parties, net	881	1,363
Other liabilities, current	881	1,363
Nonrelated party
Current liabilities
Due to related parties, net	926	1,017
Other liabilities, current	$ 926	$ 1,017

About Clover Health Investments, Corp.

Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. The company was incorporated in 2014 and is based in Franklin, Tennessee.

CEO	Mr. Andrew Toy
WEBSITE	cloverhealth.com
INDUSTRY	Healthcare Plans
EMPLOYEES	656

Clover Health Investments, Corp. Frequently Asked Questions

What is the ticker symbol for Clover Health Investments, Corp.? What does CLOV stand for in stocks?

CLOV is the stock ticker symbol of Clover Health Investments, Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Clover Health Investments, Corp. (CLOV)?

As of Fri May 17 2024, market cap of Clover Health Investments, Corp. is 437.74 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CLOV stock?

You can check CLOV's fair value in chart for subscribers.

What is the fair value of CLOV stock?

You can check CLOV's fair value in chart for subscribers. The fair value of Clover Health Investments, Corp. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Clover Health Investments, Corp. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CLOV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Clover Health Investments, Corp. a good stock to buy?

The fair value guage provides a quick view whether CLOV is over valued or under valued. Whether Clover Health Investments, Corp. is cheap or expensive depends on the assumptions which impact Clover Health Investments, Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLOV.

What is Clover Health Investments, Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CLOV's PE ratio (Price to Earnings) is -2.74 and Price to Sales (PS) ratio is 0.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLOV PE ratio will change depending on the future growth rate expectations of investors.